Why should individuals born between 1945 and 1965 be screened for hepatitis C infection?

Why Screen the 1945-1965 Birth Cohort for Hepatitis C

We screen individuals born between 1945 and 1965 for hepatitis C because this cohort accounts for 76% of all chronic HCV infections in the United States, has a prevalence five times higher than other adults (3.25%), and faces the highest risk of HCV-related death from cirrhosis and hepatocellular carcinoma after decades of undiagnosed chronic infection. 1

The Core Problem: A Hidden Epidemic in One Generation

The baby boomer generation carries a disproportionate and devastating burden of hepatitis C:

• Prevalence disparity: 3.25% of persons born 1945-1965 are HCV antibody positive, compared to <1% in other birth cohorts 2
• Mortality concentration: This cohort accounts for 73% of all HCV-associated deaths despite representing only 27% of the population 2
• Undiagnosed infections: An estimated 45-85% of chronically infected persons in this cohort remain unaware of their infection status 1

Why This Generation Specifically?

The epidemiologic explanation is straightforward: HCV incidence peaked dramatically during the 1970s and 1980s, reaching 230,000 new infections annually throughout the 1980s 1. This was before:

• Blood donor screening began in 1992
• Universal precautions were implemented in healthcare
• Widespread awareness of injection drug use risks existed

These individuals have now been living with chronic infection for 20-40 years, placing them at maximum risk for end-stage complications 1.

The Morbidity and Mortality Stakes

The clinical consequences of missing these infections are severe and quantifiable:

Projected Disease Burden Without Screening

CDC modeling estimates that without diagnosis and treatment 1:

• 1.76 million persons will develop cirrhosis during their lifetimes
• Over 400,000 will develop hepatocellular carcinoma (HCC)
• Over 1 million will die from HCV-associated disease

Current Disease Impact

• HCV is the leading indication for liver transplantation in the United States 1
• HCV accounts for >50% of incident hepatocellular carcinoma, the fastest-growing cause of cancer-related death 1
• HCV-associated deaths now exceed HIV-related deaths and increased >50% from 1999 to 2007 1

Why Risk-Based Screening Failed This Population

The previous 1998 CDC recommendations focused on testing persons with known risk factors (injection drug use, blood transfusions before 1992, hemodialysis, etc.) 1, 2. This strategy has proven inadequate for multiple reasons:

Patient-Level Barriers

• 55% of HCV-infected persons report no identifiable risk exposure 2
• Recall accuracy decreases over time: Patients cannot reliably remember drug use or other exposures from 30-40 years ago 1
• HCV infection is asymptomatic until advanced liver disease develops, giving clinicians no clinical trigger to test 1
• 50% of chronic cases would remain unidentified even if all persons with elevated ALT were tested 1
• 20-30% of infected persons have persistently normal ALT yet still develop serious liver disease 1

Provider-Level Barriers

• Many healthcare providers lack knowledge about HCV prevalence, natural history, and testing algorithms 1
• Risk-based screening requires uncomfortable conversations about stigmatized behaviors (drug use, sexual history)
• Testing rates remain suboptimal even in high-risk populations where routine testing is already recommended 1

The Treatment Imperative: Why Finding These Patients Matters Now

The advent of direct-acting antiviral therapies that can cure >95% of HCV infections in 8-12 weeks with all-oral regimens has fundamentally changed the screening calculus 3. Treatment can:

• Achieve sustained virologic response (cure) in most patients
• Halt disease progression to cirrhosis and HCC
• Reduce HCV-related mortality

This makes birth cohort screening not just diagnostic, but potentially life-saving intervention 2, 4.

The Evidence Supporting Birth Cohort Screening

The CDC issued a strong recommendation with moderate-quality evidence for one-time HCV testing of all adults born 1945-1965 without prior risk ascertainment 1, 2. This recommendation:

• Uses the GRADE framework for evidence evaluation 1
• Was developed by a 35-member workgroup including federal agencies, professional associations, and community organizations 1
• Augments but does not replace risk-based testing recommendations 1, 2

Key Supporting Data

• Birth cohort testing identifies 76.5% of all HCV antibody-positive persons in the United States 1
• Among males in this cohort, prevalence reaches 8.12% in non-Hispanic Black males and 4.05% in non-Hispanic white males 2
• 31.5% of infected persons in this cohort lack health insurance, and 57.8% consume ≥2 alcoholic drinks daily, accelerating liver disease progression 2

Clinical Implementation Algorithm

When you encounter a patient born 1945-1965:

1. Offer one-time HCV antibody testing without asking about risk factors
2. If antibody positive: Order HCV RNA (NAT) to confirm chronic infection
3. If chronically infected:
   • Perform brief alcohol screening and intervention 1
   • Refer to appropriate care for HCV treatment evaluation
   • Link to hepatology or infectious disease for treatment consideration

Common Pitfalls to Avoid

• Don't rely on ALT levels: Normal transaminases do not exclude significant HCV-related liver disease 1
• Don't skip testing based on patient denial of risk factors: Most infected persons don't recall or report exposures 2
• Don't assume asymptomatic patients are uninfected: HCV remains silent until advanced disease develops 1
• Don't forget alcohol screening: Alcohol dramatically accelerates HCV-related liver disease progression 1, 2

Updated Context (2020 Guidelines)

Note that CDC has since expanded recommendations to universal screening of all adults ≥18 years at least once in a lifetime (except in settings with HCV prevalence <0.1%) 3. However, the 1945-1965 birth cohort remains the highest-priority population due to their disproportionate disease burden and mortality risk.

The fundamental rationale remains unchanged: this generation carries three-quarters of the nation's HCV burden, faces imminent mortality from decades of chronic infection, and can now be cured with highly effective treatment—but only if we identify them first.